沐鸣娱乐-沐鸣2娱乐平台注册登录网站

Research and Development 沐鸣APP

沐鸣娱乐沐鸣赞助沐鸣游戏沐鸣体育赛事沐鸣发表

发表时间：2022/11/14 来源：Blood - 2022 ASH Annual Meeting Abstract

Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
发表时间：2022/11/14 来源：Blood - 2022 ASH Annual Meeting Abstract

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma:Long-Term Results of a Pilot Prospective Clinical Study
发表时间：2022/03/21 来源：Experimental Hematology & Oncology

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
发表时间：2021/11/04 来源：Blood - 2021 ASH Annual Meeting Abstract

CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell AcuteLymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
发表时间：2020/09/06 来源：Journal of Hematology & Oncology

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
发表时间：2020/09/04 来源：Blood - 2020 ASH Annual Meeting Abstract

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

1 2 3

我们的目标专注细胞治疗领航健康未来